F. Cidre-Aranaz

Glutaredoxin 3 (GLRX3) confers a fusion oncogene-dependent vulnerability to Ewing sarcoma

This study identifies GLRX3 as a vulnerability in Ewing sarcoma driven by EWSR1::FLI1 fusion oncoproteins, showing its role in oxidative stress and iron homeostasis and potential therapeutic targeting.

Somatic gene delivery for flexible in vivo modeling of high-risk sarcoma

This paper develops a mouse model for high-risk sarcoma by delivering genetic lesions via electroporation, generating multiple sarcoma types and validating their molecular and therapeutic relevance.

Genomic and phenotypic stability of fusion-driven pediatric Ewing sarcoma cell lines

This study compares genomic and phenotypic stability of pediatric Ewing sarcoma cell lines to adult carcinoma cell lines over 12 months of culture.

Chromosome 8 gain drives cancer progression by hijacking the translation factor 4E-BP1 sensitizing for targeted CDK4/6 inhibition

This study identifies chr8 gains and 4E-BP1 expression as prognostic markers in Ewing sarcoma, showing they drive cancer progression by promoting proliferation and sensitizing to CDK4/6 inhibitors.

A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation

This study identifies palmitate-rich metastatic niches as promoters of metastasis by enhancing p65 acetylation and NF-κB signaling in breast cancer cells.

Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma

This paper develops a gene expression strategy that exploits neomorphic DNA-binding of fusion transcription factors in pediatric sarcomas to deliver therapeutic payloads with tumor-specific efficacy.

Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

This study identifies RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma, showing its overexpression correlates with poor survival and that its inhibition reduces tumor growth and overcomes chemoresistance.

Systems biology analysis identifies TCF7L1 as a key regulator of metastasis in Ewing sarcoma

Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1

The paper identifies a 32-gene signature specific to Ewing sarcoma and shows that LOXHD1, a stereociliary protein, is a key driver of malignancy through its regulation by EWSR1-FLI1.

Cooperation of dominant oncogenes with regulatory germline variants shapes clinical outcomes in childhood cancer

This study shows how a dominant oncogene and regulatory germline variants together influence tumor growth, survival, and drug response in Ewing sarcoma.

Oncogenic hijacking of a developmental transcription factor evokes therapeutic vulnerability for ROS-induction in Ewing sarcoma

The paper identifies SOX6 as a therapeutic target in Ewing sarcoma by showing its role in elevating ROS levels, making the disease vulnerable to ROS-inducing drugs.

Expression patterns of PD-L1 and PD-1 provide rationales for immune checkpoint inhibition in soft tissue sarcomas

This study examines PD-L1 and PD-1 expression in soft tissue sarcomas and finds associations with TILs and poor clinical outcomes, supporting immune checkpoint inhibition in PD-L1-positive cases.

Biomarker-based outcome prediction in prostate adenocarcinoma depends on the TMPRSS2-ERG status

This study identifies subtype-specific prognostic biomarkers in prostate adenocarcinoma, showing that their prognostic value depends on TMPRSS2-ERG fusion status.

SOX2 expression identifies Ewing sarcoma patients with high risk for tumor relapse and poor survival

Targeting the CALCB/RAMP1-axis inhibits growth of Ewing sarcoma

This study identifies CALCB as a direct EWSR1-FLI1 target in Ewing sarcoma and shows that targeting the CALCB/RAMP1-axis inhibits tumor growth.